GSK Resolves Legal Dispute with Kimbrow, Denies Ranitidine Cancer Risk

In order to resolve the lawsuit he brought in Illinois state court, Ronald Kimbrow and GSK  have negotiated a private settlement. In this settlement, GSK disavows all culpability. As for GSK, the case will now be dismissed.

The scientific community has come to the conclusion that there is insufficient evidence to support any concern that ranitidine raises the risk of cancer, based on 16 epidemiological studies that examined data related to ranitidine usage in humans.

GSK is committed to maintaining a strong self-defence and handling this legal dispute in a way that benefits the firm and its investors.